Category: Zacks Small Cap Research

1 2 3 21 10 / 208 POSTS
Venture Capital Venture capital is the nexus between entrepreneurs, investment bankers and private investors. These stakeholders scour the investment environment to identify new ideas that are expected to show rapid growth with a modest amount ...
By David Bautz, PhDNYSE:APHBREAD THE FULL APHB RESEARCH REPORTBusiness UpdateMeeting with the FDA to Determine Regulatory Path for AB-SA01 and AB-PA01On August 9, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) provided a business update concerning the ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateContraFect Corp. (NASDAQ:CFRX) is currently conducting a Phase 2 clinical trial of CF-301, the company’s lead lysin product candidate, in patients with bacteremia, includi ...
NASDAQ:CKPTCheckpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, Canada. CK-101 is the company’s lead candidate ...
By Steven Ralston, CFANASDAQ:DSKEREAD THE FULL DSKE RESEARCH REPORTSUMMARY OF RECENT EVENTS‣ On August 9th, Daseke (NASDAQ:DSKE) announced financial results for the second quarter ending June 30, 2018.     • Total revenues increased 91.0%, primarily ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateVK5211 UpdateIn 2017, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced positive topline results from the Phase 2 study of VK5211, a selective androgen receptor modulator ...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTBusiness UpdateOPNT003 UpdateEarlier in 2018, Opiant (NASDAQ:OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development ...
Precision Biosciences is a gene editing company that was able to raise $110 million in June. They are using what is called a homing endonuclease which can potentially recognize very specific DNA sequences and replace them with new DNA sequences. ...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2018 Results: Huge Beat to Our #s. Huge Upward Revisions to Our Model and Price Target…Semler’s (OTC:SMLR) results in each of the last few quarters have indicated that the company could ...
By Lisa ThompsonNASDAQ:RVLTREAD THE FULL RVLT RESEARCH REPORTRevolution Lighting Technologies (NASDAQ:RVLT) missed its revenue guidance by reporting Q2 revenues of $36.4 million versus $43.4 million a year ago, down 16%. A few large opportunities tha ...
1 2 3 21 10 / 208 POSTS